Table 3 Linear regression analysis of baseline characteristics against disease activity status at month 12.

From: Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV

  

Active

(n = 13)

Inactive

(n = 39)

OR

(univariable)

p

OR

(multi-variable)

p

Age

Mean

(SD)

68.8

(8.2)

69.3

(8.9)

1.01

(0.94–1.09)

0.84

1.00

(0.80–1.21)

0.95

Gender, male

n (%)

8

(61.5)

25

(64.1)

0.90

(0.25–3.45)

1

0.93

(0.69–1.23)

0.87

Baseline lesion characteristics

      

 Total lesion area (mm3)

Mean

(SD)

4.2

(4.1)

4.0

(3.0)

0.98

(0.82–1.23)

0.85

0.90

(0.72–1.16)

0.36

 BNN area (mm3)

Mean

(SD)

3.3

(3.4)

2.9

(1.9)

0.93

(0.72–1.23)

0.57

0.87

(0.63–1.20)

0.34

 PL area (mm3)

Mean

(SD)

1.0

(1.0)

1.2

(1.3)

1.17

(0.70–2.65)

0.62

0.82

(0.45–1.23)

0.58

 Baseline CRT (µm)

Mean

(SD)

612.0

(188.0)

366.0

(129.5)

0.59

(0.32–0.88)

 < 0.01

0.82

(0.69–0.90)

0.02

Baseline PED characteristics

 PED height (µm)

Mean

(SD)

542.0

(298.0)

242.0

(150.0)

0.67

(0.53–0.88)

 < 0.01

0.87

(0.63–0.94)

 < 0.01

 PED volume (nl)

Mean

(SD)

2433

(1064)

799

(457)

0.94

(0.88–0.98)

 < 0.01

0.77

(0.64–0.87)

0.02

Baseline Choroidal characteristics

 Choroidal vascular Hyperpermeability (CVH)

  Absent

n (%)

3

(23.1)

20

(51.2)

Ref

 

Ref

NA

  Mild

n (%)

4

(30.8)

12

(23.1)

1.18

(0.76–2.34)

0.55

1.12

(0.80–2.23)

0.58

  Marked

n (%)

6

(46.2)

7

(17.9)

1.65

(1.05–2.45)

0.03

1.69

(1.05–3.43)

0.04

 Subfoveal Choroidal Thickness (µm)

Mean (SD)

289.0

(104.0)

258.0

(138.0)

0.83

(0.58–1.16)

0.31

0.80

(0.48–1.29)

0.37

 Choroidal Volume (nl)

Mean

(SD)

7772

(2044)

6293

(1837)

0.66

(0.44–0.93)

0.02

0.74

(0.32–1.42)

0.22

 Choroidal vascularity Index (CVI)

Mean

(SD)

63.0

(1.4)

61.8

(1.4)

0.81

(0.24–0.91)

0.02

0.78 (0.49–0.9)

0.04

Number of injections

Mean

(SD)

8

(1.0)

8

(1.0)

0.89

(0.38–1.94)

0.8

0.83

(0.53–1.25)

0.08

  1. BNN Branching neovascular network, PL polypoidal lesion, CRT central retinal thickness, PED pigment epithelium detachment, CVH choroidal vascular hyper-permeability; CVH defined as marked = presence of patchy hyper fluorescence with blurred margins persisting from the mid to the late phase ICGA, mild = fuzziness of choroidal vessels in mid-phase ICGA but no patchy hyper fluorescence in late phase, absent = none of the above features present, CV choroidal volume, CVI choroidal vascularity index. Multivariate analysis adjusted for age, sex and total number of injections. Bold fonts denote parameters significantly influencing the disease activity at month 12 from baseline and are retained in the final multivariable model.
Back to article page